Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals develops clinical-stage therapies centered on Next Generation Cancer (NGC) drug products. Company news commonly covers NGC-Cap, its lead oncology asset combining PCS6422 with capecitabine, including clinical updates in advanced or metastatic breast cancer and disclosures on metabolite exposure, safety profile and therapeutic-index objectives.
Updates also address the company's broader pipeline and business priorities, including PCS499 for focal segmental glomerulosclerosis, partnership activity for non-oncology assets, capital actions, conference participation, governance matters and operating or financial results tied to its development-stage biotechnology model.
Processa Pharmaceuticals (PCSA) announced significant developments including a successful $19.2 million public offering and uplisting to Nasdaq. The company in-licensed two clinical drug candidates, PCS12852 and PCS6422, aimed at addressing unmet medical needs in gastrointestinal disorders and cancer treatments. Key future milestones include dosing patients in multiple clinical trials in 2021. Financially, Processa reported a net loss of $3.1 million for Q3 2020, but funds from the offering will support trials in markets exceeding $1 billion.
Processa Pharmaceuticals (NASDAQ: PCSA) announced a conference call on Nov. 12, 2020, at 5:30 p.m. ET to discuss its Q3 2020 results and provide updates on its clinical pipeline. The pipeline includes three drugs targeting significant markets: PCS6422 for cancer treatment, PCS499 for a rare condition called ulcerated necrobiosis lipoidica, and PCS12852 for GI motility issues like gastroparesis. A Q&A session with CEO David Young will follow the presentation. This event aims to showcase the company’s commitment to improving patient outcomes through innovative treatments.
Processa Pharmaceuticals (NASDAQ: PCSA) has appointed Michael Floyd as Chief Operating Officer. Floyd, a serial entrepreneur with extensive experience in life sciences, aims to enhance Processa's operational efficiency and long-term strategic direction. His prior leadership roles include CEO at Arpida Ltd. and co-founder of Elion Oncology, where he contributed to the development of oncology products. With a track record of successful drug development and regulatory approval, Floyd's addition is expected to strengthen investor relations and help achieve key milestones in the company's pipeline over the next 12-18 months.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced the closing of its underwritten public offering of 4,800,000 shares of common stock at $4.00 per share, raising approximately $19.2 million. The offering was managed by Craig-Hallum Capital Group and The Benchmark Company, with National Securities Corporation as a co-manager. Funds from the offering will support the development of drug products aimed at improving the survival and quality of life for patients with high unmet medical needs. This follows the effective registration statement filed with the SEC on October 1, 2020.
Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA) announced an underwritten public offering of 4,800,000 shares of common stock at $4.00 per share, targeting gross proceeds of approximately $19.2 million. The offering is set to close on October 6, 2020, following the approval for the company's common stock to trade on the Nasdaq Capital Market effective October 2, 2020. Proceeds will be utilized for clinical trials and general corporate purposes, backed by a registration statement filed with the SEC.